Lilly ICOS' Cialis continues to outpace Pfizer's Viagra in France
US drug major Eli Lilly's joint venture Lilly ICOS has reported that its Cialis (tadalafil), claimed to be the only erectile dysfunction treatment clinically proven to work up to 36 hours for most men, has surpassed pharmaceutical giant Pfizer's Viagra (sildenafil citrate) in France for the second consecutive month.
In January, Cialis accounted for 45% of the total PDE5 inhibitor tablets sold from wholesalers to pharmacies in France; Viagra's total for the same period was 44%. For the month of February, Cialis has continued its growth in France by attaining 49% of tablets sold, while Viagra had the second largest share with 40%, according to the latest IMS market share information quoted by Lilly.
The company says that Cialis' market share in France has grown consistently since the product was introduced in Europe in February 2003. Since December 2004, the drug has secured a further 6.4 percentage points of the total share of tablets from wholesalers to pharmacies to gain the largest proportion of sales in the French market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze